• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Comment on "Association between nirmatrelvir plus ritonavir and the outcomes of non-hospitalized obese patients with COVID-19".

作者信息

Lin Ying-Li, Yu Chao-Hung, Wei James Cheng-Chung

机构信息

Department of Family Medicine, Changhua Christian Hospital, Changhua, Taiwan; Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan.

Division of Cardiovascular Medicine, Department of Internal Medicine, Changhua Christian Hospital, Changhua, Taiwan.

出版信息

Int J Antimicrob Agents. 2024 Feb;63(2):107063. doi: 10.1016/j.ijantimicag.2023.107063. Epub 2023 Dec 14.

DOI:10.1016/j.ijantimicag.2023.107063
PMID:38103754
Abstract
摘要

相似文献

1
Comment on "Association between nirmatrelvir plus ritonavir and the outcomes of non-hospitalized obese patients with COVID-19".关于“奈玛特韦联合利托那韦与非住院肥胖COVID-19患者结局之间的关联”的评论
Int J Antimicrob Agents. 2024 Feb;63(2):107063. doi: 10.1016/j.ijantimicag.2023.107063. Epub 2023 Dec 14.
2
Associations of nirmatrelvir-ritonavir treatment with death and clinical improvement in hospitalized patients with COVID-19 during the Omicron wave in Beijing, China: a multicentre, retrospective cohort study.中国北京奥密克戎疫情期间，奈玛特韦-利托那韦治疗与住院 COVID-19 患者死亡和临床改善的关联：一项多中心、回顾性队列研究。
Ann Med. 2024 Dec;56(1):2313062. doi: 10.1080/07853890.2024.2313062. Epub 2024 Feb 14.
3
Determining and Comparing the Real-World Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Patients Hospitalized With COVID-19.确定并比较莫努匹拉韦和奈玛特韦-利托那韦对新冠病毒肺炎住院患者的实际疗效。
J Korean Med Sci. 2024 Feb 19;39(6):e52. doi: 10.3346/jkms.2024.39.e52.
4
Real-Life Comparison of Antivirals for SARS-CoV-2 Omicron Infection in Patients With Hematologic Malignancies.血液系统恶性肿瘤患者感染新型冠状病毒奥密克戎变异株后抗病毒药物的真实世界比较
Influenza Other Respir Viruses. 2024;18(3):e13264. doi: 10.1111/irv.13264.
5
Additional analyses support superior efficacy of nirmatrelvir/ritonavir over molnupiravir for COVID-19.进一步分析表明，对于新冠病毒病，奈玛特韦/利托那韦比莫努匹韦疗效更佳。
J Med Virol. 2024 Feb;96(2):e29464. doi: 10.1002/jmv.29464.
6
Comparison of azvudine, molnupiravir, and nirmatrelvir/ritonavir in adult patients with mild-to-moderate COVID-19: a retrospective cohort study.阿兹夫定、莫努匹韦和奈玛特韦/利托那韦在轻中度 COVID-19 成年患者中的比较：一项回顾性队列研究。
Sci Rep. 2024 Feb 9;14(1):3318. doi: 10.1038/s41598-024-53862-y.
7
Correspondence on 'Management of nirmatrelvir/ritonavir and tacrolimus interaction in kidney transplant recipients infected by COVID-19: a three-case series'.关于“新型冠状病毒肺炎感染的肾移植受者中奈玛特韦/利托那韦与他克莫司相互作用的管理：三例系列病例”的通信
Eur J Hosp Pharm. 2024 Feb 22;31(2):178-179. doi: 10.1136/ejhpharm-2023-003701.
8
Nirmatrelvir/ritonavir use in pregnant women with SARS-CoV-2 Omicron infection: a target trial emulation.尼马曲韦/利托那韦在感染 SARS-CoV-2 奥密克戎的孕妇中的应用：一项目标试验模拟。
Nat Med. 2024 Jan;30(1):112-116. doi: 10.1038/s41591-023-02674-0. Epub 2023 Nov 1.
9
Oral Nirmatrelvir-Ritonavir Use and Clinical Outcomes in Pregnant Patients With Coronavirus Disease 2019 (COVID-19).口服尼马曲韦-利托那韦在新型冠状病毒病 2019（COVID-19）孕妇患者中的使用及临床结局。
Obstet Gynecol. 2024 Feb 1;143(2):273-276. doi: 10.1097/AOG.0000000000005471. Epub 2023 Nov 14.
10
In outpatients with COVID-19 during Omicron variant circulation, molnupiravir and nirmatrelvir-ritonavir improved outcomes.在奥密克戎变异株流行期间的 COVID-19 门诊患者中，莫努匹韦和奈玛特韦-利托那韦改善了结局。
Ann Intern Med. 2024 Jan;177(1):JC7. doi: 10.7326/J23-0108. Epub 2024 Jan 2.